Amgen Inc. (AMGN) stock prices updated...
 

Amgen Inc. stock price

Amgen Inc. latest news:


  • 09/14/2017 10:32:35

    U.S. FDA approves biosimilar version of cancer drug Avastin

    Sept 14 (Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved Amgen Inc's biosimilar version of Roche Holding AG's cancer drug Avastin.

  • 09/06/2017 23:36:22

    UK Stocks-Factors to watch on Sept 7

    Sept 7 (Reuters) - Britain's FTSE 100 index is seen opening 10 points higher at 7354.13 on Thursday, according to financial bookmakers. * RBS: Britain's financial regulator should release a leaked report about Royal Bank of Scotland that alleged many companies suffered from "inappropriate action" by its Global Restructuring Group unit, a senior British lawmaker said. * ASTRAZENECA: A new kind of injectable biotech treatment for severe asthma from AstraZeneca and Amgen promises t

  • 08/30/2017 14:12:16

    BRIEF-FDA accepts Amgen's filing of a supplemental new drug application to add overall survival results to Kyprolis® ...

    Amgen Inc(AMGN). * FDA accepts Amgen's(AMGN) filing of a supplemental new drug application to add overall survival results to Kyprolis® label. * Amgen Inc (AMGN) - FDA sets PDUFA target action date of April 30, 2018​. * Amgen Inc (AMGN) - ‍ Adverse events observed in updated analysis were consistent with those previously reported for endeavor​ Source text for Eikon: Further company coverage:

  • 08/26/2017 10:03:00

    Is the System Rigged Against Biosimilars?

    Pfizer and Amgen are encountering problems getting traction for their biosimilars. Is the system rigged against them?

  • 08/23/2017 14:47:10

    Amgen's cholesterol drug is cost-effective at $10,000 a year: study

    Amgen Inc.'s cholesterol-lowering drug Repatha is cost-effective for high-risk patients at a yearly net price of $9,669 or below, according to a new study published in the medical journal JAMA Cardiology. The analysis used data from a trial enrolling patients with established atherosclerotic cardiovascular disease, which can cause a heart attack or stroke, and used rates of those events in a typical population. Repatha's list price is more than $14,500 a year; that price does not reflect often-substantial discounts. Repatha and other cholesterol-controlling PCSK9 drugs -- intended for patients whose cholesterol levels haven't been reduced sufficiently by lifestyle changes or statins -- haven't sold as well as expected, due to, in part, their high price tags. The new JAMA Cardiology study will likely play a role in price negotiations between health insurers, which have been extremely reluctant to cover drugs like Repatha, pharmacy-benefit managers and Amgen. Amgen shares weren't active in postmarket trade. Shares have surged 9.7% over the last three months, compared with a 1.9% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 07/25/2017 14:27:38

    Amgen shares down 3% after company's guidance on lower end of expectations

    Shares of Amgen Inc. fell late Tuesday after the company beat per-share earnings expectations and sales forecasts but provided 2017 guidance on the low end of forecasts. The company said it earned $2.2 billion, or $2.91 a share, in the second quarter, compared with $1.9 billion, or $2.47 a share, in the year-ago period. Adjusted for one-time items, Amgen reported per-share earnings of $3.27, "driven by higher operating margins," it said in a statement. Revenues rose 2% to $5.8 billion, from $5.7 billion a year ago. Analysts polled by FactSet had expected adjusted earnings of $3.11 a share on sales of $5.7 billion. Shares ended the regular session down 0.1%. Amgen also tweaked its 2017 earnings guidance to between $10.79 a share and $11.37 a share and between $12.15 a share and $12.65 a share adjusted. Sales guidance was revised to a range of $22.5 billion and $23 billion. The analysts surveyed by FactSet had expected adjusted 2017 EPS of $12.49 on sales of $22.7 billion for the year. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 07/20/2017 14:34:26

    BRIEF-Amgen says FDA accepts biologics license application for Aimovig

    * FDA accepts biologics license application for Aimovig™ (erenumab)

  • 07/17/2017 10:49:14

    Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA

    Amgen Inc AMGN and partner UCB SA UCBJF announced that the FDA has issued a complete response letter CRL for the biologics license application BLA for Evenity romosozumab Amgen is looking to get Evenity approved for the treatment of postmenopausal women with osteoporosis The

  • 07/12/2017 14:18:09

    BRIEF-Amgen says second phase 3 study shows kyprolis regimen significantly improves overall survival in patients with ...

    Amgen Inc(AMGN). * Second phase 3 study shows Kyprolis regimen significantly improves overall survival in patients with relapsed multiple myeloma. * Amgen Inc(AMGN) - adverse events observed in updated analysis were consistent with those previously reported for Aspire. * Amgen Inc (AMGN) - study met key secondary endpoint.

  • 07/12/2017 14:17:57

    BRIEF-Amgen says second phase 3 study shows kyprolis regimen significantly improves overall survival in patients with relapsed multiple myeloma

    * Second phase 3 study shows Kyprolis (carfilzomib) regimen significantly improves overall survival in patients with relapsed multiple myeloma

  • More trends:

    Amicus Therapeutics, Inc.FOLD | Amkor Technology, Inc.AMKR | Amphastar Pharmaceuticals, Inc.AMPH | Amsurg Corp.AMSG | Amsurg Corp.AMSGP | Amtech Systems, Inc.ASYS | AmTrust Financial Services, Inc.AFSI | Amyris, Inc.AMRS | Anacor Pharmaceuticals, Inc.ANAC | ANADIGICS, Inc.ANAD |